Bristol-Myers Squibb Co (BMY) : Sadoff Investment Management reduced its stake in Bristol-Myers Squibb Co by 6.67% during the most recent quarter end. The investment management company now holds a total of 518,238 shares of Bristol-Myers Squibb Co which is valued at $28,725,932 after selling 37,062 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Bristol-Myers Squibb Co makes up approximately 3.19% of Sadoff Investment Management’s portfolio.
Other Hedge Funds, Including , Grubman Wealth Management sold out all of its stake in BMY during the most recent quarter. The investment firm sold 3,064 shares of BMY which is valued $169,838.Chevy Chase Trust Holdings reduced its stake in BMY by selling 29,993 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 1,430,787 shares of BMY which is valued at $78,392,820. Bristol-Myers Squibb Co makes up approx 0.43% of Chevy Chase Trust Holdings’s portfolio.Telemus Capital reduced its stake in BMY by selling 614 shares or 5.18% in the most recent quarter. The Hedge Fund company now holds 11,248 shares of BMY which is valued at $616,278. Bristol-Myers Squibb Co makes up approx 0.07% of Telemus Capital’s portfolio.Beacon Financial Group reduced its stake in BMY by selling 90 shares or 0.12% in the most recent quarter. The Hedge Fund company now holds 78,165 shares of BMY which is valued at $4,282,660. Bristol-Myers Squibb Co makes up approx 0.90% of Beacon Financial Group’s portfolio.
Bristol-Myers Squibb Co opened for trading at $55.22 and hit $55.9 on the upside on Friday, eventually ending the session at $55.43, with a gain of 0.69% or 0.38 points. The heightened volatility saw the trading volume jump to 1,27,14,378 shares. Company has a market cap of $92,616 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.